| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $33,144,763 | 4 | 100 |
Sells | $0 | 0 | 0 |
| CHILDS JOHN W | director | 1 | $25M | 0 | $0 | $25M |
| Coric Vlad | Chief Executive Officer | 1 | $5M | 0 | $0 | $5M |
| Bailey Gregory | director | 1 | $3M | 0 | $0 | $3M |
| Clark George C. | VP, Chief Accounting Officer | 1 | $144,770 | 0 | $0 | $144,770 |
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; …
Over the last 12 months, insiders at Biohaven Ltd. have bought $33.14M and sold $0 worth of Biohaven Ltd. stock.
On average, over the past 5 years, insiders at Biohaven Ltd. have bought $28.89M and sold $8.84M worth of stock each year.
Highest buying activity among insiders over the last 12 months: CHILDS JOHN W (director) — $25M. Coric Vlad (Chief Executive Officer) — $5M. Bailey Gregory (director) — $3M.
The last purchase of 17,000 shares for transaction amount of $144,770 was made by Clark George C. (VP, Chief Accounting Officer) on 2025‑11‑17.
| 2025-11-17 | Clark George C. | VP, Chief Accounting Officer | 17,000 0.0165% | $8.52 | $144,770 | +39.30% | ||
| 2025-11-13 | CHILDS JOHN W | director | 3.33M 2.9193% | $7.50 | $25M | +42.45% | ||
| 2025-11-13 | Bailey Gregory | director | 400,000 0.3503% | $7.50 | $3M | +42.45% | ||
| 2025-11-13 | Coric Vlad | Chief Executive Officer | 666,666 0.5839% | $7.50 | $5M | +42.45% | ||
| 2025-03-04 | CHILDS JOHN W | director | 28,400 0.0273% | $30.43 | $864,115 | -53.11% | ||
| 2024-12-30 | CHILDS JOHN W | director | 29,000 0.0281% | $35.94 | $1.04M | -56.01% | ||
| 2024-10-02 | Coric Vlad | Chief Executive Officer | 21,052 0.0215% | $47.50 | $999,970 | -52.63% | ||
| 2024-10-02 | CHILDS JOHN W | director | 21,052 0.0215% | $47.50 | $999,970 | -52.63% | ||
| 2024-09-24 | Bailey Gregory | director | 5,000 0.0047% | $44.19 | $220,966 | -38.02% | ||
| 2024-07-18 | CHILDS JOHN W | director | 28,400 0.0218% | $35.67 | $1.01M | +6.44% | ||
| 2024-06-17 | Car Bruce | Chief Scientific Officer | 30,000 0.0217% | $33.58 | $1.01M | +13.11% | ||
| 2024-05-30 | CHILDS JOHN W | director | 28,000 0.0214% | $35.58 | $996,240 | +5.92% | ||
| 2024-05-13 | CHILDS JOHN W | director | 28,500 0.0215% | $35.17 | $1M | +11.81% | ||
| 2024-05-13 | Bailey Gregory | director | 15,000 0.011% | $34.19 | $512,877 | +11.81% | ||
| 2024-04-24 | Bailey Gregory | director | 25,503 0.0215% | $39.18 | $999,169 | -1.32% | ||
| 2024-04-22 | Coric Vlad | Chief Executive Officer | 121,951 0.1075% | $41.00 | $5M | -0.05% | ||
| 2024-04-22 | Bailey Gregory | director | 48,780 0.043% | $41.00 | $2M | -0.05% | ||
| 2024-04-22 | CHILDS JOHN W | director | 73,170 0.0645% | $41.00 | $3M | -0.05% | ||
| 2023-12-29 | Sale | Antonijevic Irina | director | 11,000 0.0099% | $41.79 | $459,663 | -0.12% | |
| 2023-10-05 | CHILDS JOHN W | director | 454,545 0.2149% | $22.00 | $10M | +61.12% |
| CHILDS JOHN W | director | 5653904 3.7429% | $88.26M | 22 | 2 | +13.66% |
| Bailey Gregory | director | 2020071 1.3373% | $31.53M | 10 | 22 | +9.89% |
| Coric Vlad | Chief Executive Officer | 1195275 0.7913% | $18.66M | 9 | 8 | +10.59% |
| Clark George C. | VP, Chief Accounting Officer | 20000 0.0132% | $312,200.00 | 1 | 3 | |
| Cha Albert | director | 1976818 1.3086% | $30.86M | 1 | 0 | |
| Buten Matthew | Chief Financial Officer | 189380 0.1254% | $2.96M | 2 | 0 | +39.3% |
| Car Bruce | Chief Scientific Officer | 30000 0.0199% | $468,300.00 | 1 | 0 | +13.11% |
| GREGORY JULIA P | director | 25665 0.017% | $400,630.65 | 1 | 3 | +17.49% |
| Engelhart James | Chief Financial Officer | 11196 0.0074% | $174,769.56 | 2 | 9 | |
| Conway Charles | Chief Scientific Officer | 4000 0.0026% | $62,440.00 | 1 | 0 | |
| Berman Robert | Special Projects & Med Ovrsght | 341 0.0002% | $5,323.01 | 2 | 22 |
$21,345,882 | 83 | 94.45% | $2.19B | |
$52,263,649 | 70 | 1.18% | $2.49B | |
$108,353,116 | 49 | 15.41% | $2.17B | |
$586,486,795 | 47 | 4.28% | $2.38B | |
$154,047,855 | 36 | 79.21% | $2.21B |
| Increased Positions | 193 | +72.01% | 55M | +64.44% |
| Decreased Positions | 120 | -44.78% | 20M | -23.1% |
| New Positions | 75 | New | 15M | New |
| Sold Out Positions | 61 | Sold Out | 10M | Sold Out |
| Total Postitions | 341 | +27.24% | 120M | +41.34% |
| Blackrock, Inc. | $85,364.00 | 5.92% | 7.87M | +339,618 | +4.51% | 2025-09-30 |
| Janus Henderson Group Plc | $73,410.00 | 5.09% | 6.77M | +2M | +34.01% | 2025-09-30 |
| Stifel Financial Corp | $71,667.00 | 4.97% | 6.61M | +3,839 | +0.06% | 2025-09-30 |
| Suvretta Capital Management, Llc | $60,924.00 | 4.23% | 5.62M | 0 | 0% | 2025-09-30 |
| State Street Corp | $46,160.00 | 3.2% | 4.26M | +720,120 | +20.35% | 2025-09-30 |
| Vanguard Group Inc | $31,167.00 | 2.16% | 2.88M | -6M | -68.92% | 2025-09-30 |
| Bellevue Group Ag | $30,383.00 | 2.11% | 2.8M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $26,308.00 | 1.83% | 2.43M | +761,991 | +45.77% | 2025-09-30 |
| Geode Capital Management, Llc | $22,333.00 | 1.55% | 2.06M | +29,289 | +1.44% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $21,784.00 | 1.51% | 2.01M | -1M | -36.63% | 2025-09-30 |